Targeting NSD2 to treat lung adenocarcinoma
Official title: Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11336816 · Data updated 2026-11-12
Aimed at testing a new way to treat lung cancer by blocking NSD2, an epigenetic factor, to slow tumor growth in patients with lung adenocarcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $652,695 |
| NIH project number | 5R01CA272844-04 |
| Project ID | NIH-11336816 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with lung adenocarcinoma who may benefit from NSD2-targeted therapy in future trials.
✕Less likely to help
Patients with LUAD who do not respond to NSD2-targeted approaches or cannot tolerate the inhibitor may see no benefit.
What this research studies
This project explores how stopping NSD2 from modifying histones could slow or stop the progression of lung adenocarcinoma. Researchers will use cell and animal models, plus a first-in-class NSD2 inhibitor, to study how NSD2 contributes to cancer growth and how its inhibition could work with other treatments. The study will look at the molecular and cellular effects in LUAD and test the potential therapy in preclinical models to guide future clinical trials.
Why it matters
Potential benefit: If successful, the work could lead to a new targeted therapy that improves outcomes for LUAD patients.
How similar studies have gone: Preclinical evidence suggests NSD2 promotes aggressive tumor behavior, and inhibiting it may slow disease progression.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Mazur, Pawel K. — University of Tx Md Anderson Can Ctr
- Study coordinator: Mazur, Pawel K.
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.